Pretomanid (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pretomanid" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

6nih.gov

4^th place

13^th place

4fda.gov

447^th place

792^nd place

3tballiance.org

low place

3doi.org

2^nd place

4^th place

2handle.net

102^nd place

411^th place

2harvard.edu

18^th place

44^th place

2europa.eu

68^th place

182^nd place

1washingtonpost.com

34^th place

144^th place

1archive.org

6^th place

2^nd place

1semanticscholar.org

11^th place

330^th place

archive.org (Global: 6^th place; Indonesian: 2^nd place)

Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR (June 2000). "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis". Nature. 405 (6789): 962–966. Bibcode:2000Natur.405..962S. doi:10.1038/35016103. PMID 10879539. S2CID 4428584.

doi.org (Global: 2^nd place; Indonesian: 4^th place)

Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM (June 2005). "Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models". Antimicrobial Agents and Chemotherapy. 49 (6): 2294–2301. doi:10.1128/AAC.49.6.2294-2301.2005. PMC 1140539. PMID 15917524.
Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR (June 2000). "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis". Nature. 405 (6789): 962–966. Bibcode:2000Natur.405..962S. doi:10.1038/35016103. PMID 10879539. S2CID 4428584.
Abrahams KA, Batt SM, Gurcha SS, Veerapen N, Bashiri G, Besra GS (June 2023). "DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid". Nature Communications. 14 (1): 3828. Bibcode:2023NatCo..14.3828A. doi:10.1038/s41467-023-39300-z. PMC 10307805. PMID 37380634.

europa.eu (Global: 68^th place; Indonesian: 182^nd place)

ema.europa.eu

"Dovprela (previously Pretomanid FGK) EPAR". European Medicines Agency (EMA). 24 March 2020. Diakses tanggal 25 September 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Dovprela Product information". Union Register of medicinal products. Diakses tanggal 3 March 2023.

fda.gov (Global: 447^th place; Indonesian: 792^nd place)

fda.gov

"FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs". U.S. Food and Drug Administration (FDA) (Press release). 14 August 2019. Diakses tanggal 28 August 2019. Artikel ini memuat teks dari sumber tersebut, yang berada dalam ranah publik.
"Drug Trials Snapshots: Pretomanid". U.S. Food and Drug Administration (FDA). 14 August 2019. Diakses tanggal 17 March 2020.
"New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Diakses tanggal 15 September 2020.

accessdata.fda.gov

"Drug Approval Package: Pretomanid". U.S. Food and Drug Administration (FDA). 12 September 2019. Diakses tanggal 25 September 2020.

handle.net (Global: 102^nd place; Indonesian: 411^th place)

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.

harvard.edu (Global: 18^th place; Indonesian: 44^th place)

ui.adsabs.harvard.edu

Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR (June 2000). "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis". Nature. 405 (6789): 962–966. Bibcode:2000Natur.405..962S. doi:10.1038/35016103. PMID 10879539. S2CID 4428584.
Abrahams KA, Batt SM, Gurcha SS, Veerapen N, Bashiri G, Besra GS (June 2023). "DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid". Nature Communications. 14 (1): 3828. Bibcode:2023NatCo..14.3828A. doi:10.1038/s41467-023-39300-z. PMC 10307805. PMID 37380634.

nih.gov (Global: 4^th place; Indonesian: 13^th place)

pubmed.ncbi.nlm.nih.gov

Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM (June 2005). "Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models". Antimicrobial Agents and Chemotherapy. 49 (6): 2294–2301. doi:10.1128/AAC.49.6.2294-2301.2005. PMC 1140539. PMID 15917524.
Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR (June 2000). "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis". Nature. 405 (6789): 962–966. Bibcode:2000Natur.405..962S. doi:10.1038/35016103. PMID 10879539. S2CID 4428584.
Abrahams KA, Batt SM, Gurcha SS, Veerapen N, Bashiri G, Besra GS (June 2023). "DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid". Nature Communications. 14 (1): 3828. Bibcode:2023NatCo..14.3828A. doi:10.1038/s41467-023-39300-z. PMC 10307805. PMID 37380634.

ncbi.nlm.nih.gov

Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM (June 2005). "Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models". Antimicrobial Agents and Chemotherapy. 49 (6): 2294–2301. doi:10.1128/AAC.49.6.2294-2301.2005. PMC 1140539. PMID 15917524.
Abrahams KA, Batt SM, Gurcha SS, Veerapen N, Bashiri G, Besra GS (June 2023). "DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid". Nature Communications. 14 (1): 3828. Bibcode:2023NatCo..14.3828A. doi:10.1038/s41467-023-39300-z. PMC 10307805. PMID 37380634.

dailymed.nlm.nih.gov

"Pretomanid tablet". DailyMed. 15 September 2019. Diakses tanggal 25 September 2020.

semanticscholar.org (Global: 11^th place; Indonesian: 330^th place)

api.semanticscholar.org

Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR (June 2000). "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis". Nature. 405 (6789): 962–966. Bibcode:2000Natur.405..962S. doi:10.1038/35016103. PMID 10879539. S2CID 4428584.

tballiance.org (Global: low place; Indonesian: low place)

"Our Pipeline". TB Alliance. 19 July 2015. Diakses tanggal 18 April 2019.
"TB Medicine Pretomanid Enters Regulatory Review Process in the United States". TB Alliance. 8 March 2019. Diakses tanggal 18 April 2019.
"PA-824 has a New Generic Name: Pretomanid". TB Alliance. 20 October 2014. Diakses tanggal 18 April 2019.

washingtonpost.com (Global: 34^th place; Indonesian: 144^th place)

Abutaleb, Yasmeen (14 August 2019). "New antibiotic approved for drug-resistant tuberculosis". The Washington Post.